634 related articles for article (PubMed ID: 15868618)
1. Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial.
Khanna D; Furst DE; Clements PJ; Park GS; Hays RD; Yoon J; Korn JH; Merkel PA; Rothfield N; Wigley FM; Moreland LW; Silver R; Steen VD; Weisman M; Mayes MD; Collier DH; Medsger TA; Seibold JR; ;
J Rheumatol; 2005 May; 32(5):832-40. PubMed ID: 15868618
[TBL] [Abstract][Full Text] [Related]
2. The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial.
Clements PJ; Wong WK; Hurwitz EL; Furst DE; Mayes M; White B; Wigley F; Weisman M; Barr W; Moreland L; Medsger TA; Steen V; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Seibold JR
Arthritis Rheum; 2001 Mar; 44(3):653-61. PubMed ID: 11263780
[TBL] [Abstract][Full Text] [Related]
3. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.
Merkel PA; Herlyn K; Martin RW; Anderson JJ; Mayes MD; Bell P; Korn JH; Simms RW; Csuka ME; Medsger TA; Rothfield NF; Ellman MH; Collier DH; Weinstein A; Furst DE; Jiménez SA; White B; Seibold JR; Wigley FM;
Arthritis Rheum; 2002 Sep; 46(9):2410-20. PubMed ID: 12355489
[TBL] [Abstract][Full Text] [Related]
4. Correlates of the disability index of the health assessment questionnaire: a measure of functional impairment in systemic sclerosis.
Clements PJ; Wong WK; Hurwitz EL; Furst DE; Mayes M; White B; Wigley F; Weisman M; Barr W; Moreland L; Medsger TA; Steen V; Martin R; Collier D; Weinstein A; Lally E; Varga J; Weiner S; Andrews B; Abeles M; Seibold J
Arthritis Rheum; 1999 Nov; 42(11):2372-80. PubMed ID: 10555033
[TBL] [Abstract][Full Text] [Related]
5. Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study.
Khanna D; Yan X; Tashkin DP; Furst DE; Elashoff R; Roth MD; Silver R; Strange C; Bolster M; Seibold JR; Riley DJ; Hsu VM; Varga J; Schraufnagel DE; Theodore A; Simms R; Wise R; Wigley F; White B; Steen V; Read C; Mayes M; Parsley E; Mubarak K; Connolly MK; Golden J; Olman M; Fessler B; Rothfield N; Metersky M; Clements PJ;
Arthritis Rheum; 2007 May; 56(5):1676-84. PubMed ID: 17469162
[TBL] [Abstract][Full Text] [Related]
6. The minimally important difference in clinical practice for patient-centered outcomes including health assessment questionnaire, fatigue, pain, sleep, global visual analog scale, and SF-36 in scleroderma.
Sekhon S; Pope J; ; Baron M
J Rheumatol; 2010 Mar; 37(3):591-8. PubMed ID: 20080913
[TBL] [Abstract][Full Text] [Related]
7. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study.
Khanna D; Clements PJ; Furst DE; Chon Y; Elashoff R; Roth MD; Sterz MG; Chung J; FitzGerald JD; Seibold JR; Varga J; Theodore A; Wigley FM; Silver RM; Steen VD; Mayes MD; Connolly MK; Fessler BJ; Rothfield NF; Mubarak K; Molitor J; Tashkin DP;
Arthritis Rheum; 2005 Feb; 52(2):592-600. PubMed ID: 15692967
[TBL] [Abstract][Full Text] [Related]
8. Assessing disability and quality of life in systemic sclerosis: construct validities of the Cochin Hand Function Scale, Health Assessment Questionnaire (HAQ), Systemic Sclerosis HAQ, and Medical Outcomes Study 36-Item Short Form Health Survey.
Rannou F; Poiraudeau S; Berezné A; Baubet T; Le-Guern V; Cabane J; Guillevin L; Revel M; Fermanian J; Mouthon L
Arthritis Rheum; 2007 Feb; 57(1):94-102. PubMed ID: 17266096
[TBL] [Abstract][Full Text] [Related]
9. The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse scleroderma.
Sultan N; Pope JE; Clements PJ;
Rheumatology (Oxford); 2004 Apr; 43(4):472-8. PubMed ID: 14679295
[TBL] [Abstract][Full Text] [Related]
10. Validation of the Health Assessment Questionnaire disability index in patients with gout.
Alvarez-Hernández E; Peláez-Ballestas I; Vázquez-Mellado J; Terán-Estrada L; Bernard-Medina AG; Espinoza J; Aceves-Avila FJ; Goycochea-Robles MV; Garza M; Ventura L; Burgos-Vargas R;
Arthritis Rheum; 2008 May; 59(5):665-9. PubMed ID: 18438898
[TBL] [Abstract][Full Text] [Related]
11. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma.
Pope JE; Bellamy N; Seibold JR; Baron M; Ellman M; Carette S; Smith CD; Chalmers IM; Hong P; O'Hanlon D; Kaminska E; Markland J; Sibley J; Catoggio L; Furst DE
Arthritis Rheum; 2001 Jun; 44(6):1351-8. PubMed ID: 11407694
[TBL] [Abstract][Full Text] [Related]
12. Does incorporation of aids and devices make a difference in the score of the health assessment questionnaire-disability index? Analysis from a scleroderma clinical trial.
Khanna D; Clements PJ; Postlethwaite AE; Furst DE
J Rheumatol; 2008 Mar; 35(3):466-8. PubMed ID: 18085737
[TBL] [Abstract][Full Text] [Related]
13. Using a self-reported functional score to assess disease progression in systemic sclerosis.
Serednicka K; Smyth AE; Black CM; Denton CP
Rheumatology (Oxford); 2007 Jul; 46(7):1107-10. PubMed ID: 17426141
[TBL] [Abstract][Full Text] [Related]
14. A cross sectional assessment of health status instruments in patients with rheumatoid arthritis participating in a clinical trial. Minocycline in Rheumatoid Arthritis Trial Group.
Tuttleman M; Pillemer SR; Tilley BC; Fowler SE; Buckley LM; Alarcón GS; Trentham DE; Neuner R; Clegg DO; Leisen JC; Heyse SP
J Rheumatol; 1997 Oct; 24(10):1910-5. PubMed ID: 9330931
[TBL] [Abstract][Full Text] [Related]
15. A cross-sectional comparison of three self-reported functional indices in scleroderma.
Smyth AE; MacGregor AJ; Mukerjee D; Brough GM; Black CM; Denton CP
Rheumatology (Oxford); 2003 Jun; 42(6):732-8. PubMed ID: 12730528
[TBL] [Abstract][Full Text] [Related]
16. Quality of life and functional status in systemic sclerosis compared to other rheumatic diseases.
Johnson SR; Glaman DD; Schentag CT; Lee P
J Rheumatol; 2006 Jun; 33(6):1117-22. PubMed ID: 16622903
[TBL] [Abstract][Full Text] [Related]
17. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial.
Clements PJ; Hurwitz EL; Wong WK; Seibold JR; Mayes M; White B; Wigley F; Weisman M; Barr W; Moreland L; Medsger TA; Steen VD; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Furst DE
Arthritis Rheum; 2000 Nov; 43(11):2445-54. PubMed ID: 11083267
[TBL] [Abstract][Full Text] [Related]
18. The health assessment questionnaire disability index and scleroderma health assessment questionnaire in scleroderma trials: an evaluation of their measurement properties.
Johnson SR; Hawker GA; Davis AM
Arthritis Rheum; 2005 Apr; 53(2):256-62. PubMed ID: 15818719
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of functional disability using the health assessment questionnaire in Japanese patients with systemic sclerosis.
Kuwana M; Sato S; Kikuchi K; Kawaguchi Y; Fujisaku A; Misaki Y; Hatamochi A; Kondo H; Takehara K
J Rheumatol; 2003 Jun; 30(6):1253-8. PubMed ID: 12784399
[TBL] [Abstract][Full Text] [Related]
20. Psychometric properties of the Swedish version of the Scleroderma Health Assessment Questionnaire and the Cochin Hand Function Scale in patients with systemic sclerosis.
Hesselstrand R; Nilsson JÅ; Sandqvist G
Scand J Rheumatol; 2013; 42(4):317-24. PubMed ID: 23442162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
